Before Heptares was founded, the only resolved X-ray crystallography structure of a GPCR was rhodopsin. Other proteins, such as kinases, crystalize more readily, allowing chemists to employ ...

The ubiquitous presence and transmembrane location of GPCRs presented challenges, however. First, with obtaining a molecular structure around which an optimal drug could be designed, and second ...

Structure Therapeutics Inc. (NASDAQ:GPCR – Get Free Report) has been given an average rating of “Buy” by the eight research firms that are presently covering the firm, Marketbeat.com reports.

In trading on Wednesday, shares of Structure Therapeutics Inc (Symbol: GPCR) entered into oversold territory, hitting an RSI reading of 29.0, after changing hands as low as $19.61 per share.